142 páginas : ilustraciones, gráficasLa obesidad es un trastorno crónico caracterizado por un exceso de tejido adiposo; como tratamiento farmacológico se usa el Orlistat, el uso de este medicamento presenta un beneficio pero así mismo su uso genera una serie de eventos adversos que pueden ser incomodos para el paciente. Este estudio pretende describir los eventos adversos con Orlistat reportados al Programa mundial de Farmacovigilancia de Uppsala durante los años 1994 a 30 de marzo de 2018. Se realizó un estudio descriptivo de corte transversal de 28.208 casos por Orlistat y 46.027 eventos adversos reportados por la base de datos Uppsala Monitoring Center a nivel mundial durante el periodo de 1994 a 30 de Marzo de 2018. La mayoría de casos reportados corresponden a sexo femenino, de edades entre 18 y 49 años, del continente americano. Los eventos adversos más reportados fueron estreñimiento, esteatorrea, diarrea y secreción rectal. Se reportaron 52 muertesObesity is a chronic disorder characterized by an excess of adipose tissue; Orlistat is used as a pharmacological treatment, the use of this medicine presents a benefit but also its use generates a series of adverse events that may be uncomfortable for the patient. This study aims to describe the adverse events with Orlistat reported to the Uppsala Pharmacovigilance World Program during the years 1994 to March 30, 2018. A descriptive study crosscut 28,208 cases by Orlistat and 46.027 adverse events reported by the database Uppsala Monitoring Center worldwide during the period 1994 to March 30, 2018 was performed, in which a number of cases of adverse events associated with the use are presented of Orlistat that have been reported. The majority of cases were reported by female sex, with ages between 18 and 49 years, from the American continent. The most reported adverse events were constipation, steatorrhea, diarrhea and rectal secretion. 52 deaths were reportedIncluye bibliografía